Connect with us

News

Astrazeneca Covid Vaccine Established For New Essays After Scientists Raise Doubts About The Initial Data

Published

on

Drugmaker AstraZeneca is expected to begin further trials of its potential COVID-19 vaccine, after scientists raised doubts about data on its effectiveness.

The British-Swedish company, which developed the vaccine with the University of Oxford in the U.K., became the third company in a week to reveal it may have found a vaccine that was highly effective at preventing symptoms.

However, scientists had raised concerns about the vaccine’s levels of effectiveness after it emerged the interim data had been taken from two separate sub-trials—in the U.K. and Brazil—which brought varying degrees of success.

One, in which participants received two full doses a month apart, showed the vaccine was 62 percent effective. The other, in which people were given a half dose followed by a full dose, showed the vaccine was 90 percent effective.

It later emerged that the seemingly more successful method had only been tested after a contractor accidentally administered half doses to volunteers, and that it had not been tested on those older than 55, who are most at risk to COVID-19.

Neither point had been included in AstraZeneca’s original news release.

“Now that we’ve found what looks like a better efficacy we have to validate this, so we need to do an additional study,” the company’s CEO, Pascal Soriot, said on Thursday, in his first interview since the initial data were released.

It is likely to be another “international study, but this one could be faster because we know the efficacy is high so we need a smaller number of patients,” he added.

The new trial is expected to focus on the more successful half-dose, full-dose method.

Soriot said he did was not expect the additional trial to hold up regulatory approvals in the U.K. and European Union, and that authorization in some countries is still expected before the end of the year.

Approval of the vaccine by the U.S. Food and Drug Administration may take longer because the regulator is unlikely to rubber-stamp it on the basis of studies conducted elsewhere, he added.

How effective are the COVID-19 vaccine candidates?
Statista

Sponsors

Advertisement

Recent Topics

Sponsors

Recent Posts

Trending